Four Finalists Vie for $100 Mil. Aventis Drug

NEW YORK — Four finalists are making presentations this week in a review for Lantus, a diabetes drug from Aventis Pharmaceuticals, sources said.

Billings on the global account, which includes both creative and media duties, have not been determined. Sources, however, pegged them at $100 million.

The presentations are taking place on Monday and Tuesday at the client’s U.S.

AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in